Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Absolutely, I too saw the drop and started looking at why etc.
I believed then as I do now that it's a set back and nothing more. Too many sizzle stocks on AIM and I've lost too many times buying them ! Much happier and had much better returns on the non sizzle stocks, they just do their thing and eventually fulfil their end game. I've bagged many times on Faron (because I bought in after it tanked) and I'm still holding as I can still see a few bags yet and I don't really care if it takes 3 months or 3 years. This seems to me to be one if the few genuine quality companies on Aim at present.
If it hits £10 in 3 months I would be out but you know what it would be a pain as I would have to research and find a new home for the money so I'm in no real hurry as I'm a lazy arse
One of the key reasons I invested in the was Markus lack of sizzle. I notice the huge drop, read the years previous RSNs and saw a firm of honest scientist.
We can get the sizzle from the chat boards,
"Haematokine - a new treatment to rebuild Haematopoietic Stem Cells (aka blood stem cells) in patients who have lost them"
Very interesting... That explains what the AOC thing was which I never understood was when the mentioned it before.
Thanks Q&H for the conference reporting .
When I used to be in sales I was always told - sell them the sizzle , not the sausage .
Well it looks like Markku just gives you the sausage , and it's up to you to imagine the sizzle.
10p
Suurimman osan ajasta Markku oli aivan liekeissä omasta tuotteestaan ja sen tehosta ja varmaankin osa esitettävästä materiaalista oli liian teknistä/lääketieteellistä yleisölle. Ois voinut ehkä käyttää enemmän aikaa kaupalliseen potentiaaliin ja sen suunnitelman avaamiseen, nyt se kuitattiin vähän tyyliin kommentoimalla “obviously the potetial is huge”.
Alla pari screenshottia
Screenshot 2020-09-16 at 18.02.42
Screenshot 2020-09-16 at 18.02.42
1016×565 191 KB
Clevegen:
Matins:
Most of the phase 2 cohorts fully recruited
Have already candidates for the pivotal part
Remember that these are patients that have no treatment lines left currently, but we are also going to evaluate the drug in earlier treatment lines.
Markkinapotentiaali on reilusti:
Screenshot 2020-09-16 at 18.08.33
Screenshot 2020-09-16 at 18.08.33
1016×569 105 KB
Vasteet ovat olleet hyviä ORR 36% viimeisessäkin linjassa.
Screenshot 2020-09-16 at 18.10.24
Screenshot 2020-09-16 at 18.10.24
1014×568 137 KB
Screenshot 2020-09-16 at 18.12.54
Screenshot 2020-09-16 at 18.12.54
1015×569 138 KB
“We are regulating multiple receptors with clevegen, one for example CD47, to which gilead bough a molecule for a multibillion which we all know obviously. So the potential is huge”
M Jalkanen, 2020
Screenshot 2020-09-16 at 18.04.48
Screenshot 2020-09-16 at 18.04.48
1013×565 176 KB
Traumakine:
Uusi Phase 2/3 trial, jossa controlloitu streroidien käyttö.
"This not just for the covid19, but also for the influenzas, and it has potential for a orphan block buster "
Screenshot 2020-09-16 at 18.16.24
Screenshot 2020-09-16 at 18.16.24
1008×562 105 KB
Haematokine:
Saatiin tällekkin nyt alustava käyttöaihio, kuulostaa mielenkiintoiselta vaikka ollaankin todella alussa.
Regenerate Hemotopoetic stem cells lost due to cancer
Screenshot 2020-09-16 at 18.00.57
Screenshot 2020-09-16 at 18.00.57
1006×564 140 KB
Thank's for the update Q.
I don’t know the rules on whether an RNS would have to be issued. He literally spent a few seconds on Haematokine as a new therapy in the company introduction (it was named on the slide too with the words ‘AOC3-dependent cell replication’). But the rest of the presentation was Clevegen then Traumakine as usual.
Does anyone know the rules?
So we are expecting RNS on Haematokine tomorrow?
I’ve just watched Markku’s presentation.
Regarding Clevegen, he didn’t present any new data (I guess that is still under review and would require RNS anyway) but he did show plans for future trials in combination with other drugs as well as continuing as a mono-therapy.
Nothing new on Traumakine but again reiterated that results from Solidarity could come at any time.
Potentially most interesting was that he also introduced Haematokine - a new treatment to rebuild Haematopoietic Stem Cells (aka blood stem cells) in patients who have lost them. First time that has been mentioned anywhere so I’m guessing it’s the long promised ‘secret weapon’.
So now we have Clevegen, Traumakine and Haematokine.